Budesonide dry-powder inhalation - Sofotec
Alternative Names: Budecort 200 Novolizer; Budesonide Novolizer; Novolizer Budesonide; Novopulmon 200 Novolizer; S 1320 dry-powder inhalation - Sofotec; Tafen NovolizerLatest Information Update: 19 Dec 2021
At a glance
- Originator Degussa; Sofotec; University of Groningen
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 05 Aug 2016 Meda has been acquired by Mylan
- 07 Nov 2003 Budesonide 200µg Novolizer® is available for licensing outside Germany and major West European countries (http://www.viatris.com/)
- 23 Dec 2002 LEK has been acquired by Novartis